39.98
1.21%
-0.49
시간 외 거래:
39.97
-0.010
-0.03%
전일 마감가:
$40.47
열려 있는:
$40.54
하루 거래량:
611.64K
Relative Volume:
1.63
시가총액:
$3.05B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-14.59
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
+0.08%
1개월 성능:
+1.99%
6개월 성능:
-7.30%
1년 성능:
-11.59%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
39.98 | 3.05B | 13.17M | -199.06M | -156.53M | -2.74 |
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-10 | 재개 | Raymond James | Outperform |
2024-10-01 | 개시 | H.C. Wainwright | Buy |
2024-01-04 | 개시 | Citigroup | Buy |
2023-12-08 | 개시 | Robert W. Baird | Outperform |
2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
2022-12-14 | 개시 | Goldman | Buy |
2022-12-12 | 개시 | Cowen | Outperform |
2022-11-28 | 개시 | Wells Fargo | Overweight |
2022-10-19 | 개시 | Raymond James | Outperform |
2022-08-29 | 개시 | BofA Securities | Buy |
2022-07-21 | 개시 | JP Morgan | Overweight |
2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
2020-10-02 | 개시 | SVB Leerink | Outperform |
2020-07-21 | 개시 | Needham | Buy |
2020-06-01 | 재개 | Jefferies | Buy |
2020-03-25 | 개시 | Wedbush | Outperform |
2020-01-08 | 개시 | William Blair | Outperform |
2019-09-20 | 개시 | Guggenheim | Buy |
2018-08-08 | 재확인 | Stifel | Buy |
2017-03-13 | 개시 | Jefferies | Buy |
2016-10-21 | 개시 | Stifel | Buy |
2016-09-26 | 개시 | Guggenheim | Buy |
2016-04-14 | 재확인 | Jefferies | Buy |
2015-10-30 | 재개 | Jefferies | Buy |
2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Leerink Partnrs Has Bearish Outlook for XENE FY2025 Earnings - MarketBeat
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Learn to Evaluate (XENE) using the Charts - Stock Traders Daily
2,569 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Avior Wealth Management LLC - Defense World
Ian Mortimer Sells 22,468 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock - MarketBeat
Q1 EPS Estimates for Xenon Pharmaceuticals Cut by Wedbush - MarketBeat
Wedbush Lowers Earnings Estimates for Xenon Pharmaceuticals - Defense World
FY2029 Earnings Forecast for XENE Issued By Wedbush - Defense World
Cantor Fitzgerald Predicts XENE FY2025 Earnings - Defense World
Cantor Fitzgerald Estimates XENE FY2025 Earnings - MarketBeat
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Epidemic Keratoconjunctivitis Market Expected to Reach Huge - openPR
Xenon Pharmaceuticals announces executive changes - MSN
Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Assenagon Asset Management S.A. Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
Xenon Pharmaceuticals Inc. Announces Cessation of Christopher Von Seggern as Chief Commercial Office - Marketscreener.com
Barclays PLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Barclays PLC Acquires 13,903 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential - Seeking Alpha
XENE Crosses Above Key Moving Average Level - Nasdaq
Xenon Pharmaceuticals Inc (XENE-Q) QuotePress Release - The Globe and Mail
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones - TipRanks
Xenon Outlines Key Corporate Milestone Opportunities for 2025 - The Manila Times
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Trading (XENE) With Integrated Risk Controls - Stock Traders Daily
Dravet Syndrome Thereapeutics Market Size, Future Consumer Behavior and Market Dynamics (2024-2034) - 100×100 Música
Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference - TipRanks
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
JPMorgan Chase & Co. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
JPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
hVIVO (LON:HVO) Stock Price Down 6.8% – Here’s What Happened - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Barclays PLC - MarketBeat
Barclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
Stifel Financial Corp Has $849,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Franklin Resources Inc. - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares - MarketBeat
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):